Lingjuan Pang, MD, is a Medical Director of oncology for Fortrea Clinical Development Service, based in Guangzhou, Guang Dong Province, China. Dr. Pang as a member of our global team of Medical Monitors has significant medical and pharmaceutical expertise with 14 years in the industry. She has vast knowledge of oncology therapeutic experience across Phase I-III. She has built strong relationships with external research groups and Key Opinion Leaders (KOLs) to which our experience and success ensures optimal performance in clinical tirals. 

Dr. Pang earned her master degree from Sun Yet-sen University, Guangzhou, Guangdong, China, major in oncology in 2005. She joined our company in Jan, 2021.

• Over 35 years of experience in clinical research development with progressive positions in clinical operations starting as a CRA to leadership roles that led to NDA submissions 
• Conducted medical and scientific reviews across multiple therapeutic indications to identify study risks and provide solutions for trial implementation 
• Applies data-driven, analytic and innovative approaches in building the global clinical strategy and planning for Phases Ib-IV trials in renal therapeutic areas of various study designs and goals 
• Broad therapeutic expertise including rare glomerular and non-glomerular diseases, acute and chronic conditions, in-patient or out-patient studies, and outcome trials 
• Based in the United States

Liliana Baila, MD, is Senior Medical Director for Fortrea, based in Brussels, Belgium. She serves as lead project physician on clients’ drug development projects. Dr. Baila provides medical/scientific support to project teams, performs medical and safety monitoring on assigned projects, and develops and reviews protocols, case report forms and other data and materials. Dr. Baila has more than 25 years of experience as a physician, research clinician and medical director. Before joining Fortrea, she served as Clinical Research Physician for the European Organization for Research and Treatment of Cancer (EORTC) in Brussels. Dr. Baila began her career as a physician training in neonatology and pediatrics at University Hospital in Romania. She joined our company in June 2020.

Liang Wan, MD, PhD, is a Medical Director for Fortrea in Shanghai, China. He serves as lead project physician on clients’ drug development projects, provides medical/scientific expertise to project teams, reviews protocols and medical data, and is responsible for medical and safety monitoring on assigned projects. 

Dr. Wan has more than 25 years of experience as a physician, research clinician and medical director with therapeutic experience in oncology, gastroenterology, and hematology. Before joining Fortrea, he was Medical Director for IQVIA in Shanghai, serving as Global or Regional Medical Advisor on assigned projects. He began his career as a surgeon and clinical investigator at Shanghai Jiao Tong University Rui Jin Hospital. Dr. Wan joined our company in May 2019.

Leone Atkinson, MD, PhD, is the Executive Medical Director of Fortrea’s Rare Diseases, Advanced Therapies and Pediatrics Team (RAPT). She has more than 22 years of industry experience across pharmaceutical, biotechnological and CRO environments with a primary focus on rare disease drug development in Phase I-IV studies across a variety of platforms, including small molecules, biologics, RNA therapies, and gene therapies. 

Dr. Atkinson has extensive protocol design and endpoint development expertise. Her interests include expanding the role of genetic counselors in clinical trials and improving partnerships with specialized site networks and patient advocacy groups. 

She was trained as a Neurologist at Mount Sinai Medical Center, New York City and earned her Doctorate in Medical Genetics.

Dr. Gutiu is a board-certified neurologist with more than 15 years of clinical experience in a hospital setting across a wide range of neurological and psychiatric indications. He spent 10 years in academia as Assistant Professor of Neurology and attended doctoral courses in neuropharmacology. His 25 years of clinical research experience includes roles as an investigator, medical monitor and medical leadership positions spanning Phase I-IV studies. 

He has broad range of experience across product modalities, including biologics and cell and gene therapies as well as medical expertise in neuro and psychiatric diseases, including, but not limited to, neurodegenerative, pain, neuromuscular and demyelinating.

Laura Vidal, MD, is a certified medical oncologist with extensively experience in oncology drug. She holds two fellowships in Clinical Drug Development from the Royal Marsden hospital, London and the Princess Margaret Hospital, Toronto. She spent 15 years in clinical and academic positions specializing in the field on oncology and drug development. Throughout her career, Dr. Vidal has authored or co-authored dozens of peer-reviewed journal articles and received numerous health and research awards. Her research interests are focused on early phase development of targeted agents, molecular and imaging biomarkers and anticancer immunotherapy. She holds a thesis title from the London University in oncolytic viruses from her pre-clinical and clinical work in reovirus (Reolysin®). 

She joined our company in December 2020. Dr. Laura Vidal is the Medical Head of the Oncology group in EU. She contributes to the development of Fortrea policies involving medical, safety and therapeutics; serves as point of contact for key clients on business and studies oversight; manages relationships with investigators/sites for clinical trials, and mentors clinical research physicians and medical directors across the company.

Krane Huang, MD, is a Senior Medical Director, China Regional Head of Oncology for Fortrea, based in Shanghai, China. Dr. Krane has nearly 20 years of experience as medical oncologist in cancer hospitals, global pharmaceutical industries and CROs, focused on planning and execution of global oncology clinical development projects in all phases (I-III), different drug types and classes. 

Dr. Krane earned his medical degree from Tongji Medical College, Huazhong University of Science & Technology and completed his internal medicine degree and medical oncology fellowship training at Wu Union Hospital. He joined our company in September 2019.

Konstantin Haradinov, MD, is a Medical Director, Oncology for Fortrea, based in Sofia, Bulgaria. He contributes to the development of Fortrea policies involving medical, safety and therapeutics; serves as global lead project physician and provides medical and safety monitoring on assigned projects; reviews medical data and provides clinical and medical expertise to project teams and other Fortrea departments, and performs safety trend analyses. 

Dr. Haradinov has more than 15 years of experience in clinical research as a medical director and physician/oncologist. Before joining Fortrea he served as Medical Officer, Oncology, for Chiltern International in Sofia, Bulgaria. Dr. Haradinov joined our company in April 2019.

Kazuya Iwamoto, MD, PhD, MBA, FACP, is Senior Medical Director for Fortrea in Osaka, Japan. He provides medical and scientific expertise to oncology study teams on clients’ drug development projects and contributes to the development of medical strategies and execution of clinical trials. Dr. Iwamoto has more than 25 years of experience as a physician, research clinician and medical director. 

Before joining Fortrea, he was Head of the Medical Division, including Clinical Development and Medical Affairs, for Hospira Japan in Osaka. He previously served as Head of the Medical Division for Biogen Idec, Head of Medical Affairs for Bayer Yakuhin, and Clinical Research Physician for Eli Lilly in Japan. Currently President and Fellow of the Japanese Association of Pharmaceutical Medicine, Dr. Iwamoto joined our company in May 2016.